Randomized, Multicentric, Prospective Study Assessing the Effect of Adding VILDagliptin to Insulin in Hemodialysed Type 2 Diabetic Patients—The VILDDIAL Study

Randomized, Multicentric, Prospective Study Assessing the Effect of Adding VILDagliptin to Insulin in Hemodialysed Type 2 Diabetic Patients—The VILDDIAL Study

Introduction: Type 2 diabetic patients (T2D) undergoing chronic dialysis are at very high cardiovascular risk, requiring optimization of insulin treatment. Vildagliptin (Galvus), can be used in severe and terminal renal impairment (eGFR

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes (New York, N.Y.) N.Y.), 2018-07, Vol.67 (Supplement_1)
Hauptverfasser: MUNCH, MARION, SMAGALA, AGNÈS, MEYER, LAURENT, MEYER, NICOLAS, VERIER, ODILE, FLEURY, DOMINIQUE I., GUERCI, BRUNO, HANNEDOUCHE, THIERRY, CRIDLIG, JOELLE, BALTZINGER, PHILIPPE, DUCLOUX, DIDIER, BOROT, SOPHIE, KUNZ, KRISTIAN W., ALENABI, FARIDEH, WINISZEWSKI, PATRICE, CHANTREL, FRANCOIS, KESSLER, LAURENCE
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Introduction: Type 2 diabetic patients (T2D) undergoing chronic dialysis are at very high cardiovascular risk, requiring optimization of insulin treatment. Vildagliptin (Galvus), can be used in severe and terminal renal impairment (eGFR
ISSN:0012-1797
1939-327X
DOI:10.2337/db18-933-P